Using Particles That Are Smaller Than the Head of a Pin to Treat Cancer
Thanks in part to research begun more than a decade ago with funding from Women’s Health Research at Yale, Dr. W. Mark Saltzman is working with colleagues on a way to deploy effective cancer-fighting medication safely with the help of nanoparticles.
Treatment with Genetically Altered Viruses Targets and Destroys Ovarian Cancer in Mice
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
HEALTH NOTES: Black and Hispanic Cancer Patients Are Underrepresented in Clinical Trials
A new study has shown that clinical trials for new cancer medications rarely analyze data on safety and effectiveness by race and that black and Hispanic patients are consistently underrepresented among participants.
Better Science, Better Lives: Women's Health Research at Yale is Working for You
Across the country, it’s becoming clearer every day: We must study the health of women. We must study the influence of sex-and-gender differences on health. And it’s time for all aspects of medical research and practice to embrace this change.
Yale Cancer Center researchers find genetic explanations behind the rapid spread of ovarian cancer
In a breakthrough study, Yale Cancer Center (YCC) researchers have defined the genetic characteristics of primary, metastatic and recurrent ovarian tumors and evaluated new targeted therapies to treat the disease. The findings are reported today in the Proceedings of the National Academy of Science (PNAS) online early edition.
Knowing the Risks: The Genetics of Breast and Ovarian Cancer
Dr. Ryan Jensen’s work, spurred by a pair of WHRY grants, continues progress toward models uncovering how genetic mutations lead to cancer and helping guide patients and doctors toward decisions that can produce the best health outcomes.
Preventive cancer surgery to remove ovaries and fallopian tubes: Yale experts provide insight
Two years after actress Angelina Jolie’s preventive double mastectomy, her doctors removed her ovaries and fallopian tubes when a blood test showed early signs of ovarian cancer. For women with the same genetic mutations considering a similar surgery, a personalized approach that examines age and other factors should be considered, according to Yale ovarian cancer experts.
Women’s Health Research at Yale: 2012 Pilot Studies Awarded
Gender-Specific Mechanisms for Understanding Smoking Addiction, Enhancing Treatments for Breast and Ovarian Cancer, the Value of Breast Ultrasound Screening, and Cellular Mechanisms Underlying Gender Differences in Neurodegenerative Diseases
Carocari Gift to Support Dr. Schwartz’s Ovarian Cancer Research
Deborah Carocari was only 36 when she was diagnosed with a rare form of advanced but low-grade ovarian cancer. At that time she received a prognosis of several months to a year from her physician, Peter Schwartz, MD, now the John Slade Ely Professor of Obstetrics, Gynecology, and Reproductive Sciences and Vice Chair, Gynecology. Debbie went on to defy those odds and battle the cancer for the next two decades. Although she ultimately succumbed to the disease, a generous gift from her estate is now making possible further ovarian cancer research by Dr. Schwartz.